Stocks · News reference
HeartBeam, Inc. announced it will host a conference call to discuss its third quarter 2026 financial results on November 12, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HeartBeam reported positive results from a pilot study presented at the TCT 2026 conference, demonstrating that its patient-recorded 3D ECG technology is as accurate as a standard 12-lead ECG.
HeartBeam, Inc. announced it will present the results of its ALIGN-ACS study, which evaluates the company's technology for heart attack assessment, at the TCT 2026 conference on November 1, 2026.
HeartBeam, Inc. has received U.S. Food and Drug Administration (FDA) clearance for its technology designed to assess acute myocardial infarction.
HeartBeam, Inc. has successfully completed patient enrollment for its 486-patient HEADSTART-ACS study ahead of the original schedule.
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is
HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK